Loading
Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes / Treatment of Major Depression · Journal article
Translational Psychiatry · July 16, 2026
Encouraging direction, but not yet definitive.
This cross-sectional study reports graded alterations in gamma and beta power and 1/f slope across the spectrum of mild to severe depression symptoms, consistent with the hypothesis that these EEG measures scale with illness severity. The work bridges a gap between binary case–control comparisons and continuous symptom phenotyping but does not yet establish prospective validity, clinical decision thresholds, or treatment predictive utility.
Cross-sectional observational study. Individuals across a spectrum of mild to severe depression symptom presentations. Intervention: Resting-state EEG measurement of gamma power, beta power, and 1/f slope.
Graded alterations to gamma and beta power observed across spectrum of depression severity 1/f slope varies as a function of depression symptom severity EEG markers show potential utility for precision psychiatry approaches to depression assessment and treatment
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest EEG biomarkers may stratify depression severity on a continuous scale rather than as binary phenotypes. However, clinicians should recognize this is a descriptive association study that does not yet provide evidence for clinical decision-making or treatment selection.
A well-designed cross-sectional study demonstrating graded dose–response relationships between EEG biomarkers and depression severity across a continuous spectrum, but limited by lack of prospective validation, treatment outcome data, or clinical utility thresholds.
As stated by the source record.
These findings suggest EEG biomarkers may stratify depression severity on a continuous scale rather than as binary phenotypes. However, clinicians should recognize this is a descriptive association study that does not yet provide evidence for clinical decision-making or treatment selection.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Depression is a highly prevalent mental disorder that impacts an individual's functioning, societal productivity, and quality of life. It is associated with disrupted neural activity (e.g., balance of excitation-inhibition) across networks implicated in emotional processing, such as between prefrontal and limbic regions. Gamma and beta activity measured with electroencephalography (EEG) differ between healthy individuals and those with depression, and predict treatment outcomes following pharmacological intervention. However, to date research has focussed on binary comparisons between individuals with a clinical depression diagnosis relative to healthy control populations, providing limited insight into how these measures may shift as a function of illness severity. To establish the utility of EEG measures as potential biomarkers for depression, an improved understanding across the spectrum of symptom profiles is required. Here, we aimed to bridge this gap and investigate changes in beta and gamma power and the 1/f slope in resting-state EEG across a spectrum of mild to severe depression symptom presentations. In line with expectations, we demonstrate graded alterations to gamma and beta power and the 1/f slope across a spectrum of depression severity. Our findings provide critical new insights into the neurophysiological signature of depression symptoms, and highlight the utility of EEG markers to inform future precision psychiatry approaches to more effectively assess and treat depression.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.